RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...
Rivaroxaban, a direct oral anticoagulant (DOAC), demonstrated greater efficacy and similar safety compared with warfarin in patients with chronic kidney disease and atrial fibrillation. Rivaroxaban, a ...
Results of a large-scale observational study show that among patients aged 65 or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly ...
For some with atrial fibrillation, the potential for life-threatening bleeding posed by the new drugs and warfarin outweighs any benefit, independent doctors say. Consider Gloria Glatz, the woman who ...
BARCELONA -- Rivaroxaban (Xarelto) appeared risky for treating atrial fibrillation in rheumatic heart disease, the INVICTUS trial showed. Rivaroxaban increased the composite of stroke, systemic ...
The FINANCIAL — Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, on May a4 announced results from the VENTURE-AF trial. The study explored the potential of once-daily ...
NEW ORLEANS, March 18, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new real-world study, which found newly diagnosed patients with ...
Apixaban may be safer and more effective than rivaroxaban for treating nonvalvular atrial fibrillation (AF), a new observational study suggests. The study, one of the largest to compare the two drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback